Announcements
Eurosurveillance remains in the updated list of the Directory of Open Access Journals (DOAJ). It was first added to the DOAJ on 9 September 2004. Eurosurveillance is also listed in the Securing a Hybrid Environment for Research Preservation and Access / Rights MEtadata for Open archiving (SHERPA/RoMEO) [2], a database which uses a colour‐coding scheme to classify publishers according to their self‐archiving policy and to show the copyright and open access self-archiving policies of academic journals. Eurosurveillance is listed there as a ‘green’ journal, which means that authors can archive pre-print (i.e. pre-refereeing), post-print (i.e. final draft post-refereeing) and archive the publisher's version/PDF.

ESCAIDE participants are invited to the fifth Eurosurveillance scientific seminar on 30 November 2016

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Note of concern published for 'Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015', http://bit.ly/29QFXPp


In this issue


Home Eurosurveillance Edition  2015: Volume 20/ Issue 3 Article 4
Back to Table of Contents
Previous Download (pdf)
Next

Eurosurveillance, Volume 20, Issue 3, 22 January 2015
News
First Innovative Medicines Initiative Ebola projects launched
  1. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

Citation style for this article: Eurosurveillance editorial team. First Innovative Medicines Initiative Ebola projects launched. Euro Surveill. 2015;20(3):pii=21014. Available online: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=21014

The first eight projects on Ebola, selected from proposals submitted in the framework of the Innovative Medicines Initiative (IMI) first Ebola+ programme Call for proposals [1], are being launched. The projects aim to accelerate all aspects of Ebola vaccine development and manufacturing as well as deployment and compliance with vaccine regimens and diagnostics.

With a total budget of € 215 million, the eight projects cover the following fields: (i) development of Ebola vaccines, (ii) the scaling up of vaccine manufacture, (iii) compliance with vaccine regimens, and (iv) the development of rapid diagnostic tests.

The IMI Ebola+ programme was created in response to the ongoing Ebola outbreak in western Africa. The projects bring together partners from the pharmaceutical and diagnostics industries, public health bodies, academia, aid organisations, and small biotech companies in Europe, Africa and the United States. Previous experience at IMI has shown that consortia of this kind, which bring together diverse groups from different parts of the world, can make progress in even very challenging disease areas.

Further Calls for proposals are planned for the coming months. These could address issues such as the development of a vaccine that offers broad protection against both Ebola and other, related viruses such as Marburg.

The budget is partly funded by the European Union Horizon 2020 programme [2], and partly in the form of in-kind contributions from the European Federation of Pharmaceutical Industries and Associations.

For more information, see here


References
  1. The Innovative Medicines Initiative launches call on Ebola and other filoviral haemorrhagic fevers. Euro Surveill. 2014;19(45):pii=20960.
  2. European Commission.  HORIZON 2020. The EU Framework Programme for Research and Innovation. Available from:  http://ec.europa.eu/programmes/horizon2020/en/what-horizon-2020


Back to Table of Contents
Previous Download (pdf)
Next

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.